RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 TAK-875 Reduces HbA1C in Patients with T2DM
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 11
SP 10
OP 10
DO 10.1177/155989771111003
UL http://mdc.sagepub.com/content/11/11/10.abstract
AB TAK-875 is a selective G-protein-coupled receptor 40 (GPR40) agonist that is being developed as an adjunct therapy to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Results of a Phase 2 [NCT01007097] trial that has shown the glucose-lowering efficacy, safety, and tolerability of TAK-875 in a clinical setting are discussed.